AnaptysBio plans to split into two separate public companies

AnaptysBio (ANAB) announced plans to separate into two independent, publicly traded companies by the end of 2026: a royalty management firm overseeing assets like Jemperli (GSK, with Q2 2025 sales of $262M and projected peak sales of $2.7B) and a biopharma company focused on immunology therapeutics, including rosnilimab (Phase 2 data expected Dec 2025). This strategic move aims to unlock distinct asset values, with the biopharma entity launching with over two years of capital. While ANAB has seen 78% YTD returns and maintains strong liquidity, it operates at a loss, and recent malignancy concerns for Eli Lilly's competing peresolimab have added volatility, prompting Truist to reiterate a Hold rating.

Analysis

AnaptysBio has announced a strategic plan to separate its business into two independent public companies by the end of 2026, a move aimed at unlocking the distinct value of its royalty assets and its development pipeline. The proposed royalty management company will hold rights to payments from key collaborations, most notably Jemperli with GSK, which reported strong Q2 2025 sales of $262 million—a 19% quarter-over-quarter increase—and has a projected peak sales target of approximately $2.7 billion. The second entity, a biopharma company, will focus on advancing its immunology pipeline, with a key upcoming catalyst being the top-line data from the Phase 2 trial of rosnilimab in ulcerative colitis, expected by December 2025. Financially, AnaptysBio exhibits a strong liquidity position with a current ratio of 8.22, but operates at a loss with a last-twelve-months EBITDA of negative $85.6 million. Despite the company's impressive 78% year-to-date stock return, market sentiment is tempered by external factors, including a recent Hold rating reiterated by Truist Securities and emerging safety concerns over malignancy signals in Eli Lilly’s competing PD-1 agonist, which has introduced volatility and a note of caution for the asset class.

Key Decisions for Investors

• Consider the proposed separation as a potential value-unlocking event, which will allow for a clearer valuation of the stable royalty stream from GSK's Jemperli versus the higher-risk, high-reward biopharma development pipeline.
• Monitor top-line data for rosnilimab expected by December 2025 as a primary catalyst for the future biopharma entity, while also tracking any fallout from the malignancy signals observed in Eli Lilly's competing drug, which could create sector-wide headwinds.
• Given the significant 78% year-to-date stock appreciation and the reiterated Hold rating from Truist, investors should carefully assess the current valuation, as the positive outlook from the corporate restructuring may already be partially priced in.